Related references
Note: Only part of the references are listed.Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat
Jeannie Chan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Liver cholesterol: is it playing possum in NASH?
Geoffrey C. Farrell et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease
Hae-Ki Min et al.
CELL METABOLISM (2012)
Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet
Julio Cesar Fraulob et al.
CLINICAL SCIENCE (2012)
Beyond reasonable doubt: Who is the culprit in lipotoxicity in NAFLD/NASH?
Gavin E. Arteel
HEPATOLOGY (2012)
Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis
Derrick M. van Rooyen et al.
GASTROENTEROLOGY (2011)
Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation
Anna Solini et al.
JOURNAL OF HYPERTENSION (2011)
Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis
Jong In Yang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2010)
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells
Jonel Trebicka et al.
JOURNAL OF HEPATOLOGY (2010)
Statins Inhibit Angiotensin II/Smad Pathway and Related Vascular Fibrosis, by a TGF-β-Independent Process
Raul Rodrigues Diez et al.
PLOS ONE (2010)
Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor β1-mediated activation of intestinal fibroblasts
J. P. Burke et al.
BRITISH JOURNAL OF SURGERY (2009)
Update on statin-mediated anti-inflammatory activities in atherosclerosis
Fabrizio Montecucco et al.
SEMINARS IN IMMUNOPATHOLOGY (2009)
Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis
Nicole Schupp et al.
ATHEROSCLEROSIS (2008)
被撤回的出版物: Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo (Retracted article. See vol. 294, pg. 10742, 2019)
Hyoung Chul Choi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet
Naoto Matsuzawa et al.
HEPATOLOGY (2007)
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients
Giovanni Targher et al.
DIABETES CARE (2007)
Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes:: A histopathological follow-up study
Mattlas Ekstedt et al.
JOURNAL OF HEPATOLOGY (2007)
Rosuvastatin suppresses the inflammatory responses through inhibition of c-jun N-terminal kinase and nuclear factor-κB in endothelial cells
Yong Sook Kim et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome
Marie-Louise Koepke et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats
Anita Gianella et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
Kanji Yamaguchi et al.
HEPATOLOGY (2007)
Statins activate AMP-activated protein kinase in vitro and in vivo
Wei Sun et al.
CIRCULATION (2006)
Statins and hepatic steatosis: Perspectives from the Dallas Heart Study
Jeffrey D. Browning
HEPATOLOGY (2006)
RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis
K. L. Watts et al.
RESPIRATORY RESEARCH (2006)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis - The ASTEROID trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients
S Antonopoulos et al.
ATHEROSCLEROSIS (2006)
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients
G Targher et al.
DIABETES (2005)
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease
M Hamaguchi et al.
ANNALS OF INTERNAL MEDICINE (2005)
Rosuvastatin: A high-potency HMG-CoA reductase inhibitor
Larry M. Lopez
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2005)
Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects
L Sironi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats
W Jeong et al.
JOURNAL OF VETERINARY MEDICAL SCIENCE (2005)
Effects of statins on endothelium and signaling mechanisms
M Endres et al.
STROKE (2004)
Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice
T Egawa et al.
LIPIDS (2003)
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
G Marchesini et al.
HEPATOLOGY (2003)
Comparative pharmacology of rosuvastatin
F McTaggart
ATHEROSCLEROSIS SUPPLEMENTS (2003)
High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production
N Roglans et al.
LIPIDS (2002)
Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins)
M Eberlein et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands
RA DeBose-Boyd et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)